您好,欢迎来到上海士研管理咨询有限公司
士研峰会 士研智库 士研调研
嘉宾信息
李胜峰
李胜峰
所属职位: 创始人、CEO
所属公司:

百奥泰生物制药股份有限公司

李胜峰博士从事新药研发近30年。在创办百奥泰前,胜峰是旧金山湾区抗体技术公司Abmaxis (美国Merck 收购)的共同创办人和首席科学官。在此之前,就职于旧金山湾区生物技术公司COR (Millennium 收购)。1991年获得美国乔治亚大学博士,随后进入耶鲁大学生物物理和生物化学系从事博士后研究,入选耶鲁大学Donaghue Medical Research Foundation Fellow。获得过多项国际国内专利,涉及领域包括靶点发现、抗体工程、产品开发,研究成果发表于Nature, EMBO J, Gene& Dev 和PNAS 等著名期刊。2008年入选乔治亚大学研究生院“为人类未来贡献的毕业生” (Graduate Making a Difference in Our Lives and for the Future),2009年入选国家重大工程人才项目, 2010年入选广东首批科技领军人才,2011入选广州市首批领军人才(百人计划)。Shengfeng Li, Ph.D.  Founder & CEOShengfeng founded Bio-Thera in 2003, and has served since that time as Chief Executive Officer and as a member of our Board of Directors. Prior to founding Bio-Thera, Shengfeng was a founder and founding Chief Scientific Officer of Abmaxis, Inc., California (acquired by Merck). Prior to co-founding Abmaxis, he was employed at Cor Therapeutics, (merged with Millennium). Dr. Li received his Ph.D. in Microbiology from the University of Georgia in 1991, and afterwards, he worked as a postdoctoral scientist and later as a Donoghue Foundation fellow at Yale, where he identified several Raf kinase signaling regulatory molecules such as RKIP and 14-3-3 family of proteins. Dr. Li is an author on multiple publications in peer reviewed journals such as Nature, EMBO, Gene & Dev, and PNAS. He is an inventor on over 50 patents in the areas of target identification, drug discovery, antibody engineering, and product development. 

微信公众号
领导者网络APP
友情链接
Copyright ©2005 - 2017上海士研管理咨询有限公司
犀牛云提供企业云服务